Renovacor

Renovacor (NYSE:RCOR) is a preclinical stage biotechnology company that focuses on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. The company’s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses adeno-associated virus (AAV)-based gene therapies to address the monogenic cause of this severe form of heart failure. Renovacor’s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.  Following a Series A financing in 2019, Renovacor closed a reverse merger business combination with Chardan Healthcare Acquisition 2 Corp. raising gross proceeds of $95.1 million and commenced trading on the New York Stock Exchange in September, 2021.

RCOR was acquired by Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) in December, 2022.

Go to website: https://renovacor.com/